
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>2025 Focused Update of the Seoul Consensus on Gastroesophageal Reflux Disease: Evidence-based Recommendations on Acid Suppressive Therapy</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>2025 Focused Update of the Seoul Consensus on Gastroesophageal Reflux Disease: Evidence-based Recommendations on Acid Suppressive Therapy</strong></summary>
            <div>
                <ul><li>Article Type: Review or Meta-Analysis.</li><li>Journal: Journal of Neurogastroenterology and Motility (JNM).</li><li>Publication Status: Online First, Ahead of Print.</li><li>Received: July 16, 2025; Accepted: August 4, 2025.</li><li>Purpose: Refine GERD management strategies by incorporating latest evidence on acid suppressive therapies &amp; regional considerations in Asian populations.</li><li>Builds on: 2020 Seoul Consensus; integrates P-CABs &amp; adopts Lyon Consensus 2.0 diagnostic framework.</li><li>Target Audience: Gastroenterologists &amp; general healthcare providers.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What specific diagnostic framework, updated in 2023, is incorporated into the 2025 Seoul Consensus to guide individualized GERD therapy?</li><li>2. In patients with severe erosive esophagitis (LA grades C and D), which class of acid-suppressive therapy has demonstrated superior mucosal healing rates compared to the other, particularly at 4 and 8 weeks?</li><li>3. For long-term management of non-erosive reflux disease (NERD) or mild erosive esophagitis (LA grades A and B), what specific dosing strategy is recommended for PPIs or P-CABs?</li><li>4. What is the minimum percentage of expert agreement required for a recommendation statement to reach consensus using the modified Delphi method in these guidelines?</li><li>5. Beyond symptom relief, what are two major chronic complications of GERD that effective long-term treatment aims to prevent?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastroesophageal Reflux Disease (GERD) Overview</strong></summary>
            <div>
                <ul><li>GERD: chronic, relapsing GI disorder → reflux of gastric contents into esophagus/beyond.</li><li>Leads to: troublesome symptoms &amp;/or complications.</li><li>Treatment essential for: prompt symptom relief, mucosal healing, prevention of chronic complications.</li></ul>
                
        <details>
            <summary><strong>Definition &amp; Classification (Statement 1)</strong></summary>
            <div>
                <ul><li>GERD: condition characterized by regurgitation of gastric contents into esophagus/mouth → troublesome symptoms/complications.</li><li>Proven GERD: requires conclusive evidence of reflux esophagitis (LA grades B, C, D), Barrett’s esophagus, ulceration/stricture on endoscopy; OR pathological GER confirmed by ambulatory pH-impedance monitoring.</li><li>Subclassified into: Non-Erosive Reflux Disease (NERD) &amp; Erosive Reflux Disease (ERD) based on erosive esophagitis (EE).</li></ul>
                
        <details>
            <summary><strong>Erosive Esophagitis (EE) Grading</strong></summary>
            <div>
                <ul><li>Characterized by: mucosal breaks.</li><li>Graded by: Los Angeles (LA) classification.</li><li>Mild EE: LA grades A &amp; B.</li><li>Severe EE: LA grades C &amp; D.</li><li>Note: LA grade A alone may not define proven GERD per Lyon Consensus 2.0, but remains clinically relevant for subclassification &amp; phenotype-based treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Lyon Consensus 2.0</strong></summary>
            <div>
                <ul><li>Published: 2023.</li><li>Introduced: revised diagnostic framework emphasizing objective physiologic testing.</li><li>Concept: &#x27;actionable GERD&#x27; to guide individualized therapy.</li><li>Thresholds for esophageal reflux testing in Asians: may differ from Western populations; warrants further investigation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Acid-Suppressive Therapies</strong></summary>
            <div>
                <ul><li>Proton Pump Inhibitors (PPIs): cornerstone of GERD management for &gt;2 decades.</li><li>Potassium-Competitive Acid Blockers (P-CABs): emerging alternatives, first introduced in Asia.</li></ul>
                
        <details>
            <summary><strong>PPI Limitations</strong></summary>
            <div>
                <ul><li>Requires: proton pump activation.</li><li>Onset of action: delayed.</li><li>Duration of action: insufficient in some patients.</li><li>Symptom relief: incomplete in some patients.</li><li>Long-term adverse effects: growing concern.</li></ul>
                
        <details>
            <summary><strong>Potential Long-term PPI Adverse Effects</strong></summary>
            <div>
                <ul><li>Bone fractures.</li><li>Micronutrient deficiencies.</li><li>Pneumonia.</li><li>Chronic kidney disease (CKD).</li><li>Small intestinal bacterial overgrowth (SIBO).</li><li>Clostridium difficile infection.</li><li>Hypergastrinemia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>P-CAB Advantages</strong></summary>
            <div>
                <ul><li>Mechanism: reversibly inhibit H⁺, K⁺-ATPase.</li><li>Acid suppression: more potent &amp; sustained.</li><li>Stability: in acidic environments.</li><li>Onset of action: rapid.</li><li>Half-life: longer.</li><li>Evidence: increasing RCTs, real-world studies, meta-analyses support role in initial &amp; maintenance treatment.</li></ul>
                
        <details>
            <summary><strong>P-CAB Long-term Safety</strong></summary>
            <div>
                <ul><li>Data needed: further research on long-term safety.</li><li>Concerns: potential risks like hypergastrinemia, gastric malignancy, kidney dysfunction.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Guidelines Development Methodology</strong></summary>
            <div>
                <ul><li>Working Group: Gastroenterologists from Korean Society of Neurogastroenterology and Motility (KSNM) &amp; methodology experts.</li><li>Methodology: Hybrid approach combining systematic reviews, meta-analyses, &amp; expert consensuses.</li><li>Process: Modeled after 2020 Seoul Consensus &amp; recent Korean guidelines; 9 online meetings (started May 2024).</li></ul>
                
        <details>
            <summary><strong>Key Clinical Questions</strong></summary>
            <div>
                <ul><li>Developed using: PICO format (Population, Intervention, Comparator, Outcome).</li><li>Focus areas: 1) Initial treatment strategies for GERD based on disease severity; 2) Long-term maintenance approaches (on-demand vs continuous, optimal dosing).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Literature Search &amp; Selection</strong></summary>
            <div>
                <ul><li>Databases: PubMed, Embase, Cochrane Library.</li><li>Search period: Up to December 2024.</li><li>Study type: Randomized controlled trials (RCTs).</li><li>Comparisons: On-demand vs continuous PPI maintenance; P-CAB vs PPI for initial/maintenance GERD treatment.</li><li>Inclusion criteria: RCTs on GERD patients (NERD, ERD, EE, endoscopy-negative), specified comparisons, full-text articles.</li><li>Exclusion criteria: Abstract-only, unpublished, case reports, narrative reviews, systematic reviews/meta-analyses (unless used as source for evidence), conference proceedings, study protocols, insufficient data.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence &amp; Recommendation Strength</strong></summary>
            <div>
                <ul><li>Framework: GRADE (Grading of Recommendations, Assessment, Development, and Evaluation).</li><li>Evidence Levels: High, Moderate, Low, Very Low (based on study design, bias risk, consistency, directness, precision, publication bias).</li><li>Recommendation Strength: Strong (desirable effects clearly outweigh undesirable); Weak (trade-offs less certain due to low-quality evidence or uncertainty).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Consensus Process</strong></summary>
            <div>
                <ul><li>Method: Modified Delphi method.</li><li>Evaluation: 5-point Likert scale (1=strongly disagree, 5=strongly agree).</li><li>Consensus defined as: ≥80% agreement (score of 4 or 5).</li><li>Round 1: 59 expert panel members participated; all statements reached consensus.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment of GERD: Initial Strategies</strong></summary>
            <div>
                <ul><li>Recommendations stratified by disease severity (NERD, mild EE, severe EE).</li></ul>
                
        <details>
            <summary><strong>NERD / Mild Erosive Esophagitis (EE) (Statement 2)</strong></summary>
            <div>
                <ul><li>Recommendation: Standard dose PPIs / P-CABs once daily for 4-8 weeks.</li><li>Level of Evidence: High.</li><li>Strength of Recommendation: Strong.</li><li>Expert Opinion: Strongly agree 70.7%; Agree w/ reservation 25.9%.</li></ul>
                
        <details>
            <summary><strong>Efficacy: PPIs vs P-CABs</strong></summary>
            <div>
                <ul><li>Mild EE healing rates @ 8 weeks: Comparable (pooled RR = 1.00; 95% CI, 0.99-1.02).</li><li>Mild EE healing rates @ 4 weeks: Comparable (pooled RR = 1.01; 95% CI, 0.97-1.06).</li><li>Vonoprazan subgroup: Comparable (RR = 1.00; 95% CI, 0.98-1.01).</li><li>Other P-CABs (fexuprazan, keverprazan, zastaprazan): Comparable (RR = 1.01; 95% CI, 0.98-1.05).</li><li>Tegoprazan (all EE grades): Comparable efficacy to PPI @ 4 &amp; 8 weeks (pooled RR = 1.03; 95% CI, 0.97-1.10).</li><li>NERD symptom relief: P-CABs superior vs placebo.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety: PPIs vs P-CABs</strong></summary>
            <div>
                <ul><li>Overall incidence of treatment-emergent adverse events (TEAEs) over 8 weeks: Comparable (pooled RR = 1.04; 95% CI, 0.94-1.15).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Standard Doses Examples</strong></summary>
            <div>
                <ul><li>PPIs: lansoprazole 30 mg, esomeprazole 40 mg, pantoprazole 40 mg.</li><li>P-CABs: tegoprazan 50 mg, fexuprazan 40 mg, zastaprazan 20 mg, vonoprazan 20 mg.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Severe Erosive Esophagitis (EE) (Statement 3)</strong></summary>
            <div>
                <ul><li>Recommendation: Standard dose P-CABs / PPIs once daily for 8 weeks.</li><li>Level of Evidence: High.</li><li>Strength of Recommendation: Weak.</li><li>Expert Opinion: Strongly agree 50.0%; Agree w/ reservation 37.9%.</li></ul>
                
        <details>
            <summary><strong>Consideration</strong></summary>
            <div>
                <ul><li>P-CABs may offer superior mucosal healing efficacy compared to PPIs in patients w/ severe EE.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Efficacy: PPIs vs P-CABs</strong></summary>
            <div>
                <ul><li>Severe EE healing rates @ 8 weeks: Superior w/ P-CABs (pooled RR = 1.10; 95% CI, 1.00-1.20).</li><li>Severe EE healing rates @ 4 weeks: Superior w/ P-CABs (pooled RR = 1.14; 95% CI, 1.03-1.26).</li><li>Vonoprazan subgroup: Superior efficacy vs PPIs (RR = 1.13; 95% CI, 1.04-1.23).</li><li>Other P-CABs (fexuprazan, keverprazan, zastaprazan): Comparable efficacy (RR = 1.04; 95% CI, 0.81-1.34).</li><li>Treatment failure rates (failure to heal EE): Significantly lower w/ P-CABs (8.9% vs PPI 19.4%; P &lt; 0.0001).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety: PPIs vs P-CABs</strong></summary>
            <div>
                <ul><li>Overall incidence of TEAEs over 8 weeks: Comparable (pooled RR = 1.04; 95% CI, 0.94-1.15).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Preference</strong></summary>
            <div>
                <ul><li>P-CABs may be preferred over PPIs due to superior healing efficacy in severe EE &amp; comparable safety profiles.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment of GERD: Long-term Maintenance Strategies</strong></summary>
            <div>
                <ul><li>Essential for managing GERD → high relapse rates after acid-suppressive therapy cessation.</li><li>Strategies: continuous, on-demand, intermittent, threshold therapies.</li><li>Most widely adopted: continuous &amp; on-demand.</li></ul>
                
        <details>
            <summary><strong>NERD / Mild Erosive Esophagitis (EE) (Statement 4)</strong></summary>
            <div>
                <ul><li>Recommendation: On-demand therapy w/ PPI / P-CAB.</li><li>Level of Evidence: Moderate.</li><li>Strength of Recommendation: Weak.</li><li>Expert Opinion: Strongly agree 63.8%; Agree w/ reservation 29.4%.</li></ul>
                
        <details>
            <summary><strong>PPI On-demand vs Continuous</strong></summary>
            <div>
                <ul><li>Treatment failure rates: Comparable (pooled RR = 1.17; 95% CI, 0.65-2.13).</li><li>Adverse events: Similar incidence (RR = 0.98; 95% CI, 0.89-1.09).</li><li>Pill burden: Significantly lower w/ on-demand therapy (risk difference = –0.52; 95% CI, –0.62 to –0.42).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>P-CAB On-demand Therapy</strong></summary>
            <div>
                <ul><li>Evidence: Remains limited for long-term maintenance.</li><li>Effectiveness: Suggested by some studies in NERD/mild EE.</li><li>Support: Individual studies, meta-analyses, &amp; superior pharmacological properties (rapid onset, long-lasting effects).</li><li>P-CAB vs PPI (mild EE): P-CAB superior in preventing EE recurrence over 24 weeks (pooled RR = 0.60; 95% CI, 0.38-0.94).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Severe Erosive Esophagitis (EE) (Statement 5)</strong></summary>
            <div>
                <ul><li>Recommendation: Continuous daily therapy w/ P-CAB / PPI.</li><li>Level of Evidence: Low.</li><li>Strength of Recommendation: Weak.</li><li>Expert Opinion: Strongly agree 46.6%; Agree w/ reservation 37.9%.</li></ul>
                
        <details>
            <summary><strong>Rationale for Continuous Therapy</strong></summary>
            <div>
                <ul><li>Elevated risk of complications: Barrett’s esophagus, peptic strictures, esophageal cancer.</li><li>High rate of: symptomatic &amp; endoscopic relapse following treatment discontinuation.</li><li>Reflected in: most international guidelines.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Continuous PPI vs On-demand</strong></summary>
            <div>
                <ul><li>Effectiveness: Continuous PPI therapy may be more effective.</li><li>Relapse rates: Significantly higher in on-demand group, particularly in severe EE.</li><li>Treatment failure &amp; symptom relief: Continuous maintenance therapy more effective.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>P-CAB vs PPI</strong></summary>
            <div>
                <ul><li>EE recurrence prevention over 24 weeks: P-CAB superior (pooled RR = 0.60; 95% CI, 0.44-0.83).</li><li>Treatment failure rates (endoscopic recurrence): Significantly lower w/ P-CABs (23.3% vs PPI 39.9%; P = 0.001).</li><li>Long-term safety: Further studies required to establish profiles.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dose Optimization for Long-term Safety (Statement 6)</strong></summary>
            <div>
                <ul><li>Recommendation: Lowest effective dose that controls symptoms &amp; maintains mucosal healing.</li><li>Level of Evidence: Low.</li><li>Strength of Recommendation: Weak.</li><li>Expert Opinion: Strongly agree 83.1%; Agree w/ reservation 15.2%.</li></ul>
                
        <details>
            <summary><strong>Rationale</strong></summary>
            <div>
                <ul><li>Avoid: overuse &amp; potential risks associated w/ long-term acid suppression.</li><li>Periodic reassessment: therapeutic indications, doses, durations of therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Long-term PPI Risks</strong></summary>
            <div>
                <ul><li>↑ risks of: enteric infection, kidney dysfunction, nutrient malabsorption, cardiovascular events, dementia, gastric malignancy, hypomagnesemia, vitamin B12 deficiency, bone fracture.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Long-term P-CAB Risks</strong></summary>
            <div>
                <ul><li>Concerns: hypergastrinemia, gastric malignancy, kidney dysfunction.</li><li>Research needed: further clarification on long-term safety, especially given recent clinical adoption.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guideline Emphasis</strong></summary>
            <div>
                <ul><li>Japanese guidelines: minimize dose &amp; duration, allow long-term maintenance when clearly indicated.</li><li>American Gastroenterological Association: reassess appropriateness &amp; dosing within 12 months, ideally via endoscopic &amp; reflux monitoring.</li><li>American College of Gastroenterology: PPIs generally safe, but potential risks for long-term use must be considered.</li><li>Adjustment: based on individual clinical responses, risk factors, &amp; evolving indications.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion &amp; Perspectives</strong></summary>
            <div>
                <ul><li>Guidelines provide: evidence-based approach for GERD diagnosis &amp; management.</li><li>Emphasis: recent advances in acid-suppressive therapy &amp; evolving GERD definition.</li><li>Integration: P-CAB data w/ established PPI evidence.</li><li>Recommendations stratified by: disease severity (NERD, mild EE, severe EE) for initial &amp; long-term maintenance.</li><li>Future Research: ongoing research, especially on long-term P-CAB safety, is essential.</li><li>Further studies warranted for: pediatric GERD &amp; extraesophageal manifestations.</li><li>Revision: guidelines will be periodically revised w/ accumulating evidence for optimal clinical outcomes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
